The study done by Cai et al. [42] showed that human breast cancer cell lines which were engineered to express OCT3 achieved >13 times metformin uptake and >4 times antiproliferative effects compared to the control group without OCT3. This evidence concerns the gene SLC22A3 and breast carcinoma.